Dow Jones

40 211,72

0,53%

DAX

Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.

S'inscrire

Accueil
Investir
Actions
Etats-Unis
NASDAQ
Allos Therapeutics, Inc. (MM) (ALTH)
Allos Therapeutics, Inc. (MM) (ALTH) Actualités

ALTH

Allos Therapeutics, Inc. (MM) (ALTH)

Allos Therapeutics, Inc. (MM)

De:

Actualités Réglementées

Mots clefs:

Trier par:

Actualités Non-réglementées

Showing the most relevant articles for your search:NASDAQ:ALTH

<< Précédent 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Suivant >>

Date	Heure	Source	Titre	Symbole	Société
07/07/2009	14h00	Business Wire	Allos Therapeutics Completes Enrollment in Randomized Phase 2b Trial of Pralatrexate in Patients with Advanced Non-Small Cell...	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
29/06/2009	14h40	PR Newswire (US)	InvestorSoup.com Researches Market Movers: Applied Materials, Allscripts-Misys, Allos, ValueVision, BGC Partners and Warren Reso	NASDAQ:ALTH
24/06/2009	00h46	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
12/06/2009	18h53	Edgar (US Regulatory)	Current report filing (8-K)	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
02/06/2009	12h05	Edgar (US Regulatory)	Proxy Statement (definitive) (DEF 14A)	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
30/05/2009	14h00	Business Wire	Allos Therapeutics Reports Updated Data from Pivotol Phase 2 PROPEL Study of Pralatrexate at 45th ASCO Annual Meeting	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
26/05/2009	14h00	Business Wire	Allos Therapeutics Announces FDA Accepts Pralatrexate NDA for Filing and Grants the Application Priority Review Status	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
15/05/2009	00h15	Business Wire	Allos Therapeutics Announces Updated Data from Pivotol Phase 2 PROPEL Study of Pralatrexate to be Presented at ASCO 2009	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
12/05/2009	14h00	Business Wire	Allos Therapeutics to Present at the Eighth Annual JMP Securities Research Conference	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
05/05/2009	23h01	Edgar (US Regulatory)	Quarterly Report (10-Q)	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
05/05/2009	22h00	Business Wire	Allos Therapeutics Reports First Quarter 2009 Financial Results	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
30/04/2009	14h31	Edgar (US Regulatory)	Amended Annual Report (10-K/A)	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
28/04/2009	22h00	Business Wire	Allos Therapeutics to Report First Quarter 2009 Results on May 5, 2009	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
19/04/2009	21h00	Business Wire	Allos Therapeutics’ Pralatrexate Demonstrates Anticancer Activity in Multiple Cancer Cell Lines	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
15/04/2009	14h00	Business Wire	Allos Therapeutics to Present at the American Association for Cancer Research Annual Meeting 2009	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
03/04/2009	22h00	Business Wire	Allos Therapeutics Announces Closing of Common Stock Offering	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
02/04/2009	22h10	Edgar (US Regulatory)	Prospectus filed pursuant to Rule 424(b)(5) (424B5)	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
31/03/2009	15h00	Business Wire	Allos Therapeutics Announces Pricing of Common Stock Offering	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
26/03/2009	13h00	Business Wire	Allos Therapeutics to Present at the 4th Annual Citi Biotech Day	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
25/03/2009	13h00	Business Wire	Allos Therapeutics Submits New Drug Application for Pralatrexate for Patients with Relapsed or Refractory Peripheral T-cell L...	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
24/03/2009	22h30	Edgar (US Regulatory)	Initial Statement of Beneficial Ownership (3)	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
24/03/2009	13h00	Business Wire	Allos Therapeutics Appoints David M. Stout to Its Board of Directors	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
17/03/2009	13h00	Business Wire	Allos Therapeutics’ Pralatrexate Granted Orphan Medicinal Product Designation for the Treatment of Bladder Cancer by the Eu...	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
03/03/2009	22h00	Business Wire	Allos Therapeutics Reports 2008 Results	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
26/02/2009	22h00	Business Wire	Allos Therapeutics to Report 2008 Results on March 3, 2009	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
17/02/2009	22h24	Edgar (US Regulatory)	Amended Statement of Ownership (SC 13G/A)	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
13/02/2009	22h49	Edgar (US Regulatory)	Annual Statement of Changes in Beneficial Ownership (5)	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
09/12/2008	22h00	Business Wire	Allos Therapeutics to Present at the RBC Capital Markets 2008 Healthcare Conference	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
07/12/2008	17h03	Business Wire	Allos Therapeutics Announces Top Line Results from Pivotal Phase 2 PROPEL Trial of Pralatrexate in Patients with Relapsed or ...	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
06/12/2008	18h30	Business Wire	Two Pralatrexate Studies Presented at the 50th Annual Meeting of the American Society of Hematology	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)